MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ioannou, M.
Right arrow Articles by Synetos, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ioannou, M.
Right arrow Articles by Synetos, D.

Vol. 53, Issue 6, 1089-1096, June 1998

Kinetics of Inhibition of Rabbit Reticulocyte Peptidyltransferase by Anisomycin and Sparsomycin

Margarita Ioannou, Charalambos Coutsogeorgopoulos, and Dennis Synetos

Laboratory of Biochemistry, School of Medicine, University of Patras, 26110 Patras, Greece

A detailed kinetic study was carried out on the inhibitory mechanisms of two eukaryotic peptidyltransferase drugs (I), anisomycin and sparsomycin. In an in vitro system from rabbit reticulocytes, AcPhe-puromycin is produced in a pseudo-first-order reaction from the preformed AcPhe-tRNA/poly(U)/80S ribosome complex (complex C) and excess puromycin (S). This reaction is inhibited by anisomycin and sparsomycin through different mechanisms. Anisomycin acts as a mixed noncompetitive inhibitor. The product, AcPhe-puromycin, is derived only from C according to the puromycin reaction. On the other hand, sparsomycin reacts with complex C in a two-step reaction,            C<IT>+</IT>I <AR><R><C><IT> K<SUB>i</SUB> </IT></C></R><R><C><IT>⇌</IT></C></R><R><C> </C></R></AR>:CI <AR><R><C><IT>k</IT><SUB><IT>6</IT></SUB></C></R><R><C><IT>⇌</IT></C></R><R><C><IT>k</IT><SUB><IT>7</IT></SUB></C></R></AR>:<IT> </IT>C<SUP>∗</SUP>I    An initial rapid binding of the drug produces the encounter complex CI. During this step and before conversion of CI to C*I, sparsomycin behaves as a competitive inhibitor. The rapidly produced CI is isomerized slowly to a conformationally altered species C*I in which I is bound more tightly. The rate constants of this step are k6 = 2.1 min-1 and k7 = 0.095 min-1. Moreover, the low value of the association rate constant k7/Ki' (2 × 105 M-1 sec-1), provides insight into the rates of possible conformational changes occurring during protein synthesis and supports the proposal that sparsomycin is the first example of a slow-binding inhibitor of eukaryotic peptidyltransferase. When complex C is preincubated with concentrations of sparsomycin of >8 Ki and then reacts with a mixture of puromycin and sparsomycin, the inhibition becomes linear mixed noncompetitive and involves C*I instead of CI. During this phase, AcPhe-puromycin is produced from a new, modified ribosomal complex with a lower catalytic rate constant. Thus, sparsomycin also acts as a modifier of eukaryotic peptidyltransferase activity.


Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Biol. Bull.Home page
D. A. Pace and D. T. Manahan
Cost of Protein Synthesis and Energy Allocation During Development of Antarctic Sea Urchin Embryos and Larvae
Biol. Bull., April 1, 2007; 212(2): 115 - 129.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Q. Wang, M. T. H. Abreu, K. Siminovitch, G. P. Downey, and C. A. McCulloch
Phosphorylation of SHP-2 Regulates Interactions between the Endoplasmic Reticulum and Focal Adhesions to Restrict Interleukin-1-induced Ca2+ Signaling
J. Biol. Chem., October 13, 2006; 281(41): 31093 - 31105.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
B. Lizak, I. Czegle, M. Csala, A. Benedetti, J. Mandl, and G. Banhegyi
Translocon pores in the endoplasmic reticulum are permeable to small anions
Am J Physiol Cell Physiol, September 1, 2006; 291(3): 511 - 517.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
M. Flourakis, F. Van Coppenolle, V. Lehen'kyi, B. Beck, R. Skryma, and N. Prevarskaya
Passive calcium leak via translocon is a first step for iPLA2-pathway regulated store operated channels activation
FASEB J, June 1, 2006; 20(8): 1215 - 1217.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
A. Toulouse, F. Au-Yeung, C. Gaspar, J. Roussel, P. Dion, and G. A. Rouleau
Ribosomal frameshifting on MJD-1 transcripts with long CAG tracts
Hum. Mol. Genet., September 15, 2005; 14(18): 2649 - 2660.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
F. Van Coppenolle, F. Vanden Abeele, C. Slomianny, M. Flourakis, J. Hesketh, E. Dewailly, and N. Prevarskaya
Ribosome-translocon complex mediates calcium leakage from endoplasmic reticulum stores
J. Cell Sci., August 15, 2004; 117(18): 4135 - 4142.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Roy and W. F. Wonderlin
The Permeability of the Endoplasmic Reticulum Is Dynamically Coupled to Protein Synthesis
J. Biol. Chem., February 7, 2003; 278(7): 4397 - 4403.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. L. Law, A. Raney, C. Heusner, and D. R. Morris
Polyamine Regulation of Ribosome Pausing at the Upstream Open Reading Frame of S-Adenosylmethionine Decarboxylase
J. Biol. Chem., October 5, 2001; 276(41): 38036 - 38043.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics